science
AstraZeneca shares fall after Wainua trial misses death reduction goal
AstraZeneca shares declined after its drug Wainua did not lower death rates in a heart condition study. The company reported the trial results and investors reacted to the outcome.
Jul 9, 3:42 AM·1m read2 sources
marketwatch.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
AstraZeneca shares declined after the company reported that its drug Wainua did not reduce deaths in a trial for a heart condition. The study tested Wainua in patients with the condition. Company officials said the drug failed to meet the primary goal of lowering mortality rates.
Trading volume increased as shares moved lower following the announcement. The company did not provide additional details on next steps for the drug. Investors reviewed the trial data released by AstraZeneca. No further updates on regulatory plans were included in the initial statement.
Transparency
How sources framed this
These outlets didn't split into competing frames — coverage was uniform.
CorroborationLimited · 2 sources
